US drugmaker Eagle Pharmaceuticals (Nasdaq: EGRX) has signed a definitive agreement to acquire an early-stage biotechnology firm with proprietary viscosity-reducing technology and formulation know-how.
The acquisition of USA-based Arsia Therapeutics will mark Eagle’s entry into biologics, the fastest growing sector of the pharmaceuticals market, and will allow the company to apply its proven market strategy to offer “biobetter” formulations, and to aid in the rapid development of novel biologics.
The closing of the acquisition is expected to occur within the next week, subject to the satisfaction of various customary closing conditions. Eagle’s shares closed down 5.6% at $79.50 on Friday following the announcement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze